

Ning Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9432725/publications.pdf>

Version: 2024-02-01

37
papers

9,854
citations

777949

13
h-index

445137

33
g-index

37
all docs

37
docs citations

37
times ranked

17102
citing authors

#	ARTICLE	IF	CITATIONS
1	Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1107-1110.	1.0	359
2	Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 7579-7586.	0.5	2
3	A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, , .	1.5	2
4	Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e4-e6.	0.7	5
5	Different manifestations of patients with inhibitors against prothrombin and thrombin. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 164-167.	1.0	0
6	Significantly Prolonged Prothrombin Time and Activated Partial Thromboplastin Time with no Bleeding Tendency: A Patient with Lupus Anticoagulantâ€“Hypoprothrombinemia Syndrome Positive for Immunoglobulin M Anti-Phosphatidylserine/Prothrombin complex Antibodies. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 507-511.	1.5	4
7	Two cases of von Willebrand disease type 3 in consanguineous Chinese families. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1075.	0.6	4
8	Deep intronic F8 c.5999-27A>G variant causes exon 19 skipping and leads to moderate hemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 476-480.	0.5	3
9	Normal activated partial thromboplastin time in Chinese patients with mild hemophilia B. <i>Hematology</i> , 2020, 25, 484-488.	0.7	0
10	Response to â€œLupus anticoagulant is frequent in patients with Covidâ€“19â€“(JTHâ€“2020â€“00483). <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2065-2066.	1.9	25
11	Characteristics of emergency patients with markedly elevated D-dimer levels. <i>Scientific Reports</i> , 2020, 10, 7784.	1.6	14
12	Coagulation Dysfunction. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1223-1229.	1.2	50
13	ISTH interim guidance on recognition and management of coagulopathy in COVIDâ€“19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1023-1026.	1.9	1,513
14	Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1094-1099.	1.9	2,925
15	Specific coagulation markers may provide more therapeutic targets in COVIDâ€“19 patients receiving prophylactic anticoagulant. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2428-2430.	1.9	29
16	Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 580-586.	1.0	127
17	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 844-847.	1.9	4,615
18	Congenital fibrinogen disorder caused by digenic mutations of the FGA and FGB genes. <i>Hematology</i> , 2020, 25, 145-148.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Type and dose of heparin in Covid-19: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 2063-2064.	1.9	19
20	DOACs and newer hemophilia therapies in COVID-19: Reply. Journal of Thrombosis and Haemostasis, 2020, 18, 1795-1796.	1.9	17
21	Response to 'Pulmonary thrombosis in 2019-nCoV pneumonia?'. Journal of Thrombosis and Haemostasis, 2020, 18, 1513-1514.	1.9	4
22	Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'. Journal of Thrombosis and Haemostasis, 2020, 18, 1520-1521.	1.9	27
23	Laboratory haemostasis monitoring in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 2058-2060.	1.9	25
24	Response to 'Inaccurate conclusions by Tang and colleagues'. Journal of Thrombosis and Haemostasis, 2020, 18, 1798-1798.	1.9	3
25	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. , 2020, 18, 844.		1
26	IVS9+5G>A mutation causes moderate haemophilia A. Haemophilia, 2019, 25, e132-e135.	1.0	1
27	PROS1 IVS10+5G>A mutation causes hereditary protein S deficiency in a Chinese patient with pulmonary embolism and venous thromboembolism. Thrombosis Research, 2019, 174, 1-4.	0.8	6
28	Significantly prolonged PT and APTT could indicate a wide spectrum of clinical manifestations in three patients with plasma cell disorders. International Journal of Laboratory Hematology, 2019, 41, e23-e26.	0.7	2
29	Determining the cutoff value of the APTT mixing test for factor VIII inhibitor. Clinical Chemistry and Laboratory Medicine, 2019, 57, e88-e90.	1.4	3
30	Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. American Journal of the Medical Sciences, 2018, 355, 350-356.	0.4	1
31	Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report. BMC Medical Genetics, 2018, 19, 163.	2.1	1
32	Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients. Thrombosis Research, 2018, 172, 9-13.	0.8	23
33	Effects of hemolysis and lipemia interference on kaolin-activated thromboelastography, and comparison with conventional coagulation tests. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 98-103.	0.6	4
34	Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays. American Journal of the Medical Sciences, 2017, 354, 22-26.	0.4	3
35	The Value of Thromboelastography for Bleeding Risk Prediction in Hematologic Diseases. American Journal of the Medical Sciences, 2016, 352, 502-506.	0.4	12
36	The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 223-229.	0.6	10

#	ARTICLE	IF	CITATIONS
37	Time course of soluble P-selectin and von Willebrand factor levels in trauma patients: a prospective observational study. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2013, 21, 70.	1.1	13